Tardive Dyskinesia clinical trials
The registry lists 62 studies for Tardive Dyskinesia across more than 10 countries. 9 are recruiting or about to start. 47 of them are mainly about Tardive Dyskinesia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Tardive Dyskinesia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Neurocrine Biosciences (13) · Luye Pharma Group Ltd. (4) · Auspex Pharmaceuticals, Inc. (3) · Beijing HuiLongGuan Hospital (2) · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan (2) · Emory University (2) · Shanghai Mental Health Center (2) · Beersheva Mental Health Center (2)
What is being tested here
Drugs under test in Tardive Dyskinesia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Valbenazine | 1 | 4 | 14 |
| Deutetrabenazine | 1 | 3 | 4 |
| LPM3770164 | 1 | 0 | 4 |
| Varenicline | 1 | 0 | 1 |
| Pyridoxine | 0 | 1 | 2 |
| Olanzapine | 0 | 0 | 2 |
| Aripiprazole | 0 | 0 | 2 |
| Tetrabenazine | 0 | 1 | 1 |
| Pimavanserin | 0 | 0 | 1 |
| Metformin | 0 | 0 | 1 |
Drug classes tested here Antipsychotics 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Feb 2027Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia · Neurocrine Biosciences
- Apr 2027A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms · Shanghai Mental Health Center
- Oct 2027Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · University Hospitals Cleveland Medical Center
Who these studies take
Of the 7 Tardive Dyskinesia studies recruiting now, 2 (29%) set no upper age limit and 4 (57%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 7 (100%) | 7 (100%) |
| 30 | 7 (100%) | 7 (100%) |
| 40 | 7 (100%) | 7 (100%) |
| 50 | 7 (100%) | 7 (100%) |
| 65 | 6 (86%) | 6 (86%) |
| 75 | 5 (71%) | 5 (71%) |
| 85 | 3 (43%) | 3 (43%) |
Across all 62 studies, recruiting or not: 58% stop at 75 or younger and 34% at 65; 3% take children; 0% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 → or search them.
- Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaRecruitingNCT07365462Phase 23 countries
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 41 country
- A Computer-Assisted Tool for Objective Assessment of Extrapyramidal SymptomsNot yet recruitingNCT077159941 country
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental DisabilitiesRecruitingNCT06997198Phase 41 country
- Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TDRecruitingNCT07173920Not applicable1 country
- Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaRecruitingNCT06731868Phase 1/21 country
- Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient OutcomesRecruitingNCT06011408Not applicable1 country
- Studying Patterns in Patient Engagement Among Tardive Dyskinesia PatientsNot yet recruitingNCT062187191 country
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesRecruitingNCT03495024Phase 41 country
- Addressing Involuntary Movements in Tardive DyskinesiaCompletedNCT02291861Phase 36 countries
- Efficacy of Docosahexaenoic Acid on Tardive DyskinesiaWithdrawnNCT00621634Phase 21 country
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 41 country
- Efficacy and Safety of MT-5199 in Subjects With Tardive DyskinesiaCompletedNCT03176771Phase 2/31 country
- Xenazine in Late Dyskinetic Syndrome With NeurolepticsCompletedNCT01543321Phase 31 country
- Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With ValbenazineWithdrawnNCT05053321Phase 11 country
- ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement DisordersActive, not recruitingNCT02252380Not applicable1 country
- Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsCompletedNCT06216054Phase 11 country
- Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsCompletedNCT06474650Phase 11 country
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental DisabilitiesWithdrawnNCT06107829Phase 41 country
- A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsCompletedNCT05238701Phase 11 country
- Randomized Controlled Trial of Pyridoxine for Tardive DyskinesiaCompletedNCT03287778Not applicable1 country
- Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive DyskinesiaCompletedNCT03497013Not applicable1 country
- Reducing Involuntary Movements in Participants With Tardive DyskinesiaCompletedNCT02198794Phase 36 countries
- Aim to Reduce Movements in Tardive DyskinesiaCompletedNCT02195700Phase 2/34 countries
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedNCT03891862Phase 42 countries
- A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive DyskinesiaWithdrawnNCT02064010Phase 21 country
- Pimavanserin Treatment in TSCompletedNCT04794413Early Phase 11 country
- The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineCompletedNCT03698331Phase 42 countries
- Safety and Efficacy of Propranolol in the Treatment of Tardive DyskinesiaWithdrawnNCT03254186Phase 2/3
- Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive DyskinesiaTerminatedNCT00917293Phase 22 countries
- Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaCompletedNCT02736955Phase 31 country
- Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 33 countries
- D-Serine Treatment For Tardive DyskinesiaStatus unknownNCT01804920Not applicable1 country
- Validation of the Implantation of a New Electrode for the Treatment of DystoniaTerminatedNCT02509338Not applicable1 country
- Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.Status unknownNCT02840760Not applicable1 country
- Heart Rate Variability in Response to Metformin ChallengeCompletedNCT02500628Phase 21 country
- Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic AgentsStatus unknownNCT030620331 country
- Dysport for the Treatment of OMDCompletedNCT01921270Phase 1/21 country
- NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 22 countries
- NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 21 country
- NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 22 countries
- A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 33 countries
- Deep Brain Stimulation for Patients With Tardive Dyskinesia and or DystoniaTerminatedNCT02524886Not applicable1 country
- The Assessment of Movement Disorders Utilizing Live Two-Way VideoCompletedNCT014670891 country
- Melatonin Treatment for Tardive Dyskinesia in SchizophreniaCompletedNCT01391390Not applicable1 country
- Sarizotan in the Treatment of Neuroleptic-induced Tardive DyskinesiaTerminatedNCT00310661Not applicable2 countries
- Levetiracetam Treatment of Tardive DyskinesiaCompletedNCT00291213Phase 31 country
- Pyridoxal Kinase Activity in Tardive DyskinesiaWithdrawnNCT01908452Phase 31 country
- Movement Disorders Caused by Antipsychotic Drugs in Older PatientsCompletedNCT00255879Phase 11 country
- Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in SchizophreniaCompletedNCT00401089Phase 1/22 countries